Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis
Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and…